An Annals of Oncology study of about 230,000 adults with obesity linked GLP-1 use to fewer obesity-related cancers, though it can't show the drugs caused it.
Recap by typeshit. Full story at health enews.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
Known for cancer blockbusters, AstraZeneca is chasing the market built by Wegovy and Mounjaro with a weight loss drug of its own.
He says this average comes from his own clinical experience, adding that some strong responders drop more than 10 kg. A personal observation, not trial data.
Loading…